|
Jul 24
|
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
|
|
Jul 24
|
Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
|
|
Jul 24
|
Rocket lays off staff; Abivax capitalizes on immune drug data
|
|
Jul 15
|
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
|
|
Jul 15
|
Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug
|
|
Jul 14
|
Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)
|
|
Jan 21
|
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
|
|
Jan 21
|
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
|
|
Jan 17
|
ATRA Stock Down After FDA Issues CRL for Rare Blood Cancer Candidate
|
|
Jan 16
|
Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application
|
|
Jan 16
|
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)
|
|
Jan 2
|
Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why
|
|
Jun 21
|
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases
|
|
Jun 12
|
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
|
|
May 11
|
Atara Biotherapeutics First Quarter 2024 Earnings: Beats Expectations
|
|
May 9
|
Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 9
|
Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
|
|
Apr 5
|
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Mar 28
|
Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 28
|
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
|